The role of immunotherapy in the management of patients with malignant melanoma

James E Goodnight Jr, Donald L. Morton

Research output: Contribution to journalArticle

4 Scopus citations

Abstract

Immunotherapy using a variety of agents may be beneficial in controlling accessible cutaneous melanoma metastases and may have potential for limiting the growth of systemic disease when used in the adjuvant setting. Approximately 20% of patients with metastases limited to the skin can be brought into complete remission with local, intralesional BCG immunotherapy. Dinitrochlorobenzene (DNCB), vaccinia virus, C. parvum, and transfer factor have also been tested for activity in local immunotherapy. BCG, DNCB, and vaccinia virus appear to be the most effective. Adjuvant immunotherapy has shown some promise, particularly with regard to improvement in survival. In a study of adjuvant immunotherapy with BCG in patients with stage II disease, recurrence rates were similar, but of those patients who developed recurrences, those who received BCG lived significantly longer. Immunotherapy, used either alone or in combination with chemotherapeutic agents, has shown little or no activity in the treatment of metastatic malignant melanoma.

Original languageEnglish (US)
Pages (from-to)309-319
Number of pages11
JournalWorld Journal of Surgery
Volume3
Issue number3
DOIs
StatePublished - May 1979

ASJC Scopus subject areas

  • Surgery

Fingerprint Dive into the research topics of 'The role of immunotherapy in the management of patients with malignant melanoma'. Together they form a unique fingerprint.

  • Cite this